

ASSIGNMENT AGREEMENT

This assignment agreement ("Assignment") is entered into the 1st day of July, 2025 ("Effective Date") by and between **INOZYME PHARMA, INC., ("Assignor")**, a US company with an address at 321 Summer Street, Suite 400, Boston, Massachusetts 02210 and **BIOMARIN PHARMACEUTICAL INC. ("Assignee")**, a US company with an address at 105 Digital Drive, Novato, California 94949.

For good and valuable consideration, the receipt and sufficiency of which are agreed, Assignor hereby irrevocably sells, assigns and transfers to Assignee and its successors, assigns and legal representatives, Assignor's entire right, title and interest, both legal and equitable, throughout the world, in the patent properties listed in **Schedule A**, and to the inventions described therein and improvements thereof, all related patent applications throughout the world including those claiming priority thereto anywhere in the world, the right of priority, including without limitation to claim priority benefit of or to said patent applications, all continuations, divisionals and continuations-in-part of any of the foregoing, patents issuing from any of the foregoing, and reissues, reexaminations, supplemental examinations, inter partes reviews, oppositions, post-grant reviews, extensions and foreign equivalents thereof and supplementary protection certificates allowed on any of the foregoing (collectively the "Patent Rights") for Assignee's own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made; together with all income, royalties, damages or payments due or payable as of the Effective Date or thereafter, including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Patent Rights, with the right to sue for, and collect the same for its own use and enjoyment, and for the use and enjoyment of its successors, assigns, or other legal representatives.

Upon the request of Assignee, the undersigned agrees to execute and/or have the inventor(s), its employees, agents, or others execute any and all documents and take actions reasonably requested to effectuate this assignment and Assignee's rights in the Patent Rights, including any oath or affidavit relating thereto, to cooperate to the best of the ability of the undersigned with Assignee in preparing and executing statements and giving and producing evidence in support of the Patent Rights, and to perform any and all acts reasonably requested by Assignee to obtain, enforce and defend the Patent Rights and vest all rights therein to Assignee as fully and entirely as the same would have been held and enjoyed by the undersigned if this Assignment had not been executed.

The parties execute this valid and binding assignment as of the Effective Date.

INOZYME PHARMA, INC. (ASSIGNOR)

Signature: Eric Fleckop

Name: Eric Fleckop

Title: Authorized Signatory, Director and Secretary

Date: 11/18/25

~~United States of America)
State of California) ss.:
County of Marin)~~

~~On this _____ day of _____, _____, before me
personally came _____ to me known to be the individual
described in and who executed the foregoing instrument, and acknowledged execution
of the same.~~

Notary Public

Please see attached certificate.

CALIFORNIA ACKNOWLEDGMENT

CIVIL CODE § 1189

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.


State of California

County of Marin

On November 18, 2025 before me, Lisa Nguyen, Notary Public,
Date Here Insert Name and Title of the Officer

personally appeared Eric Stanton Fleekap
Name(s) of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Place Notary Seal and/or Stamp Above

Signature [Signature]
Signature of Notary Public

OPTIONAL

Completing this information can deter alteration of the document or fraudulent reattachment of this form to an unintended document.

Description of Attached Document

Title or Type of Document: _____

Document Date: _____ Number of Pages: _____

Signer(s) Other Than Named Above: _____

Capacity(ies) Claimed by Signer(s)

Signer's Name: _____

☐ Corporate Officer – Title(s): _____

☐ Partner – ☐ Limited ☐ General

☐ Individual ☐ Attorney in Fact

☐ Trustee ☐ Guardian or Conservator

☐ Other: _____

Signer is Representing: _____

Signer's Name: _____

☐ Corporate Officer – Title(s): _____

☐ Partner – ☐ Limited ☐ General

☐ Individual ☐ Attorney in Fact

☐ Trustee ☐ Guardian or Conservator

☐ Other: _____

Signer is Representing: _____

BIOMARIN PHARMACEUTICAL INC. (ASSIGNEE)

Signature: Luisa Bigornia

Name: Luisa Bigornia

Title: Group Vice President, Intellectual Property

Date: November 18, 2025

United States of America)
State of California) ss.:
County of Marin)

On this _____ day of _____, _____, before me
personally came _____, to me known to be the individual
described in and who executed the foregoing instrument, and acknowledged execution
of the same.

Notary Public

Please see attached certificate.

CALIFORNIA ACKNOWLEDGMENT


CIVIL CODE § 1189

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California }

County of MarinOn November 18, 2025 before me, Lisa Nguyen, Notary Public,
Date Here Insert Name and Title of the Officerpersonally appeared Luisa Bigornia
Name(s) of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.



I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature

Signature of Notary Public

Place Notary Seal and/or Stamp Above

OPTIONAL

Completing this information can deter alteration of the document or fraudulent reattachment of this form to an unintended document.

Description of Attached Document

Title or Type of Document: _____

Document Date: _____ Number of Pages: _____

Signer(s) Other Than Named Above: _____

Capacity(ies) Claimed by Signer(s)

Signer's Name: _____

☐ Corporate Officer – Title(s): _____☐ Partner – ☐ Limited ☐ General☐ Individual ☐ Attorney in Fact☐ Trustee ☐ Guardian or Conservator☐ Other: _____

Signer is Representing: _____

Signer's Name: _____

☐ Corporate Officer – Title(s): _____☐ Partner – ☐ Limited ☐ General☐ Individual ☐ Attorney in Fact☐ Trustee ☐ Guardian or Conservator☐ Other: _____

Signer is Representing: _____

Schedule A

Client No.	Matter No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Publication No	Publication Date	Application Title
30610	70001P1	US	Expired	62/794,450	18-Jan-2019					NPP1 Gene Therapy
30610	70002P1	US	Expired	62/821,692	21-Mar-2019					TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70002P2	US	Expired	62/877,044	22-Jul-2019			WO 2020/150716	23-Jul-2020	TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001	PC	Expired	PGT/US/01/04296	20-Jan-2020			US-2021-0187067-A1	24-Jun-2021	TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001	US	Abandoned	17/178,127	17-Feb-2021					TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001	AU	Pending	202/0207967	20-Jan-2020				21-Sep-2021	TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001	BR	Published	BR11.20210133941.9	20-Jan-2020			3,126,839	23-Jul-2020	TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001	CA	Published	3,126,839	20-Jan-2020			CH11.5651033 A	05-Nov-2021	TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001	CN	REGISTERED/GRANTED	202/08000984.9	20-Jan-2020	2120208000984.9	15-Oct-2024	50111452	24-Nov-2021	TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001	EP	Published	207412100.9	20-Jan-2020			2022-517435	08-Mar-2022	TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001	JP	Published	2021-541712	20-Jan-2020	7724156	06-Aug-2025	10-2021-0142599	25-Nov-2021	TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001	KR	Published	10-2021-7025330	20-Jan-2020			202120107	20-Feb-2023	TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001	RU	Published	20211210107	20-Jan-2020					TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001	IL	Pending	284699	20-Jan-2020					TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001	MX	Pending	NK/A/2021/008503	20-Jan-2020			40063782		TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001	HK	REGISTERED/GRANTED	620/20252974.2	05-May-2022	40063782	16-May-2025	40064291	24-Jun-2022	TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001HK	HK	Published	620/20253488.2	13-May-2022			US-2023-0031809-A1	30-Jun-2022	TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001A	US	Published	17/822,245	25-Aug-2022			2025-084821	02-Feb-2023	TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70001A	JP	Published	2025-027352	20-Jan-2020				03-Jun-2025	TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3
30610	70003P1	US	Expired	63/030,870	27-May-2020			WO 2021/743054	02-Dec-2021	COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	PC	Expired	PGT/US/1/34576	27-May-2021			202214259	16-Apr-2022	COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	TW	Published	110119287	27-May-2021			US-2023-0330307-A1	19-Oct-2023	COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	US	Published	18/058,712	23-Nov-2022					COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	AU	Pending	2021281267	27-May-2021			8B11.2022024053.8	04-Jul-2023	COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	BR	Published	BR11.2022024053.8	27-May-2021			3180119	02-Dec-2021	COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	CA	Published	3,180,119	27-May-2021			118367851	30-Jun-2023	COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	CN	Published	202189043445.6	27-May-2021			4157328	05-Apr-2023	COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	EP	Published	21812363.6	27-May-2021					COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	IL	Pending	298482	27-May-2021			2023-527365	28-Jun-2023	COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	JP	Published	2022-572586	27-May-2021			10-2023-0047334	07-Apr-2023	COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	KR	Published	10-2022-7045745	27-May-2021					COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	MX	Pending	NK/A/2022/014733	27-May-2021					COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	RU	Pending	2022134275	27-May-2021					COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	CO	Published	NC2/022/0018016	27-May-2021			2022/0018016	26-Jan-2023	COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	IN	Pending	202427075674	27-May-2021			40093023A	29-Dec-2023	COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003	HK	Published	62023082331.7	08-Nov-2023			WO 2021/743031	02-Dec-2021	COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004P1	US	Expired	63/030,840	27-May-2020			202212570	01-Apr-2022	COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	PC	Expired	PGT/US/1/34533	27-May-2021			US-2023-0372455-A1	23-Nov-2023	COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	TW	Published	110119288	23-Nov-2022					COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	US	Published	18/058,715	23-Nov-2022			8B11.2022024143.7	07-Feb-2023	COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	AU	Pending	2021282350	27-May-2021			3179982	02-Dec-2021	COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	BR	Published	BR11.2022024143.7	27-May-2021			116406581	07-Jul-2023	COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	CA	Published	3,179,982	27-May-2021			4157329	05-Apr-2023	COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	CN	Published	20218065245.3	27-May-2021					COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	EP	Published	21812898.1	27-May-2021			2023-527364	28-Jun-2023	COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	IL	Pending	298484	27-May-2021			10-2023-0048480	11-Apr-2023	COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	JP	Published	2022-572585	27-May-2021					COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	KR	Published	10-2022-7045747	27-May-2021			2022/0018399	16-Feb-2023	COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	MX	Pending	NK/A/2022/014717	27-May-2021			40093024A	29-Dec-2023	COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	RU	Published	2022134425	27-May-2021					COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	CO	Published	NC2/022/0018399	27-May-2021					COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	IN	Pending	202427075680	27-May-2021					COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70004	HK	Published	62023082332.5	08-Nov-2023					COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL ARTERY DISEASE
30610	70003P2	US	Expired	63/030,882	27-May-2020					COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70003P3	US	Expired	63/030,890	27-May-2020					COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION
30610	70005P1	US	Expired	63/047,793	02-Jul-2020			WO 2022/006545	06-Jan-2022	COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	PC	Expired	PGT/US/1/40356	02-Jul-2021			202216186	01-May-2022	COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	TW	Published	110124480	02-Jul-2021			US-2024-0016951-A1	18-Jan-2024	COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	US	Published	18/148,888	30-Dec-2022					COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	AU	Pending	2013300261	02-Jul-2021			8B11.2022026807-2	24-Jan-2023	COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	BR	Published	BR11.2022026907.2	02-Jul-2021			3184349	06-Jan-2022	COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	CA	Published	3,184,349	02-Jul-2021			116322742	23-Jun-2023	COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	CN	Published	202180059861.8	02-Jul-2021			4175657	10-May-2023	COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	EP	Published	21831757.6	02-Jul-2021					COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	IL	Pending	299503	02-Jul-2021			2023-532732	31-Jul-2023	COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	JP	Published	2022-581569	02-Jul-2021			10-2023-0048020	10-Apr-2023	COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	KR	Published	10-2023-7003831	02-Jul-2021					COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	MX	Published	NK/A/2023/000247	02-Jul-2021			2023/000754	16-Feb-2023	COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	RU	Pending	2023102180	02-Jul-2021			202347006231	23-Feb-2024	COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	CO	Published	NC2/022/000754	02-Jul-2021			40093025A	29-Dec-2023	COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	IN	Published	202347006231	02-Jul-2021					COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
30610	70005	HK	Published	62023082333.3	08-Nov-2023					COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY

306.0	7000.6P1	US	Expired	63/047.877	02-Jul-2020						COMPOSITIONS AND METHODS FOR TREATING MOYAMOYA DISEASE AND MOYAMOYA SYNDROME
306.0	7000.7P1	US	Expired	63/047.865	02-Jul-2020						COMPOSITIONS AND METHODS FOR PREVENTING OR INHIBITING INTIMAL PROLIFERATION
306.0	7000.7P2	US	Expired	63/047.883	02-Jul-2020						COMPOSITIONS AND METHODS FOR PREVENTING OR INHIBITING INTIMAL PROLIFERATION
306.0	7000.7P3	US	Expired	63/047.874	02-Jul-2020						COMPOSITIONS AND METHODS FOR PREVENTING OR INHIBITING INTIMAL PROLIFERATION
306.0	7000.5P2	US	Expired	63/047.848	02-Jul-2020						COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY
306.0	7000.8P1	US	Expired	63/116.086	19-Nov-2020						TREATMENT OF ENPP1 DEFICIENCY
306.0	7000.8	PC	Expired	PC7/US21/60207	19-Nov-2021			WO2022/109844		27-May-2022	TREATMENT OF ENPP1 DEFICIENCY AND ABCG6 DEFICIENCY
306.0	7000.8P2	US	Expired	63/219.229	07-Jul-2021						TREATMENT OF ENPP1 DEFICIENCY
306.0	7000.8	TW	Expired	110/43.242	19-Nov-2021			2022.35.00		16-Sep-2022	Treatment of ENPP1 deficiency and ABCG6 deficiency
306.0	7000.9P1	US	Expired	63/327.215	04-Apr-2022						TREATMENT OF ENPP1 DEFICIENCY AND ABCG6 DEFICIENCY
306.0	7000.8	US	Published	18/319.821	18-May-2023			US-2024-01.81021-A1		06-Jun-2024	TREATMENT OF ENPP1 DEFICIENCY AND ABCG6 DEFICIENCY
306.0	7000.8	AU	Pending	202138.380	19-Nov-2021						TREATMENT OF ENPP1 DEFICIENCY AND ABCG6 DEFICIENCY
306.0	7000.8	BR	Published	BR11.202.3009612-0	19-Nov-2021			BR11.202.3009612-0		27-Jun-2023	TREATMENT OF ENPP1 DEFICIENCY AND ABCG6 DEFICIENCY
306.0	7000.8	CA	Published	3.198.967	19-Nov-2021			3.198.967		27-May-2022	TREATMENT OF ENPP1 DEFICIENCY AND ABCG6 DEFICIENCY
306.0	7000.8	CN	Published	202180087.759.6	19-Nov-2021			1167.01.22		05-Sep-2023	TREATMENT OF ENPP1 DEFICIENCY AND ABCG6 DEFICIENCY
306.0	7000.8	EP	Published	218957.19.9	19-Nov-2021			4247.406		27-Sep-2023	TREATMENT OF ENPP1 DEFICIENCY AND ABCG6 DEFICIENCY
306.0	7000.8	IL	Pending	302.954	19-Nov-2021						TREATMENT OF ENPP1 DEFICIENCY AND ABCG6 DEFICIENCY
306.0	7000.8	JP	Published	2023-580.551	19-Nov-2021			2024-502.885		09-Jan-2024	TREATMENT OF ENPP1 DEFICIENCY AND ABCG6 DEFICIENCY
306.0	7000.8	KR	Published	10-2023-7017.319	19-Nov-2021			10-2023-01239.32		24-Aug-2023	TREATMENT OF ENPP1 DEFICIENCY AND ABCG6 DEFICIENCY
306.0	7000.8	MX	Pending	NK/A/2023/0058.36	19-Nov-2021						TREATMENT OF ENPP1 DEFICIENCY AND ABCG6 DEFICIENCY
306.0	7000.8	RU	Pending	202311.5785	19-Nov-2021						TREATMENT OF ENPP1 DEFICIENCY AND ABCG6 DEFICIENCY
306.0	7000.8	CO	Published	NC2023/0007.726	19-Nov-2021			2023/0007.726		21-Jul-2023	TREATMENT OF ENPP1 DEFICIENCY AND ABCG6 DEFICIENCY
306.0	7000.8	IN	Pending	202347.040.978	19-Nov-2021			4009.302.2A		29-Dec-2023	TREATMENT OF ENPP1 DEFICIENCY AND ABCG6 DEFICIENCY
306.0	7000.8	HK	Published	620230823.30.9	08-Nov-2023						Treatment of ABCG6 Deficiency
306.0	7001.0P1	US	Expired	63/116.106	19-Nov-2020						Treatment of ABCG6 Deficiency
306.0	7001.0P2	US	Expired	63/237.351	26-Aug-2021						Treatment of ABCG6 Deficiency
306.0	7001.1P1	US	Expired	63/116.093	19-Nov-2020						Treatment of ABCG6 Deficiency
306.0	7001.2P1	US	Expired	63/089.515	08-Oct-2020						Treatment of ABCG6 Deficiency
306.0	7001.2P2	US	Expired	63/165.650	24-Mar-2021						Treatment of ABCG6 Deficiency
306.0	7001.2P3	US	Expired	63/248.339	24-Sep-2021						Treatment of ABCG6 Deficiency
306.0	7001.2	PC	Expired	PC7/US21/542.16	08-Oct-2021			WO.202.2/076.948		14-Apr-2022	Treatment of ABCG6 Deficiency
306.0	7001.2	AR	Published	921010.819	12-Oct-2021			1237.70		11-Jun-2023	Treatment of ABCG6 Deficiency
306.0	7001.2	TW	Published	110.137.622	08-Oct-2021			2022.295.57		01-Aug-2022	Treatment of ABCG6 Deficiency
306.0	7001.2	US	Published	18/297.228	07-Apr-2023			US-2024-01.48907-A1		09-May-2024	Treatment of ABCG6 Deficiency
306.0	7001.2	AU	Pending	202135.6692	08-Oct-2021						Treatment of ABCG6 Deficiency
306.0	7001.2	CA	Published	3.195.071	08-Oct-2021			3195.071		14-Apr-2022	Treatment of ABCG6 Deficiency
306.0	7001.2	EP	Published	218786.35.8	08-Oct-2021			4225.927		16-Aug-2023	Treatment of ABCG6 Deficiency
306.0	7001.2	JP	Published	2023-571.661	08-Oct-2021			2023-548.758		21-Nov-2023	Treatment of ABCG6 Deficiency
306.0	7001.2	HK	Published	620230826.49.2	15-Nov-2023			4009.306.4		29-Dec-2023	Treatment of ABCG6 Deficiency
306.0	7001.3	US	Published	18/063.263	08-Dec-2022			US-2023-03.131.98-A1		05-Oct-2023	Treatment of ABCG6 Deficiency
306.0	7001.3P1	US	Expired	63/036.833	09-Jun-2020						Treatment of ABCG6 Deficiency
306.0	7001.3	PC	Expired	PC7/US21/364.94	08-Jun-2021			WO.202.1/252.549		16-Dec-2021	Treatment of ABCG6 Deficiency
306.0	7001.3	AR	Published	921010.1571	09-Jun-2021			1225.78		21-Sep-2022	Treatment of ABCG6 Deficiency
306.0	7001.3	TW	Published	110.120.998	09-Jun-2021			2022.148.49		16-Apr-2022	Treatment of ABCG6 Deficiency
306.0	7001.3	AU	Pending	202128.6502	08-Jun-2021						Treatment of ABCG6 Deficiency
306.0	7001.3	BR	Published	BR11.202.2024858-6	08-Jun-2021			BR11.202.2024858-6		27-Dec-2022	Treatment of ABCG6 Deficiency
306.0	7001.3	CA	Published	3.181.983	08-Jun-2021			3181.983		16-Dec-2021	Treatment of ABCG6 Deficiency
306.0	7001.3	CN	Published	202180059006.4	08-Jun-2021			1161.571.45		23-May-2023	Treatment of ABCG6 Deficiency
306.0	7001.3	EP	Published	217368.50.5	08-Jun-2021			4162.066		12-Apr-2023	Treatment of ABCG6 Deficiency
306.0	7001.3	IL	Pending	298.853	08-Jun-2021						Treatment of ABCG6 Deficiency
306.0	7001.6	JP	Published	2022-575.745	08-Jun-2021			2023-529.892		12-Jul-2023	Treatment of ABCG6 Deficiency
306.0	7001.3	KR	Published	10-2023-7000.507	08-Jun-2021			10-2023-00422.63		28-Mar-2023	Treatment of ABCG6 Deficiency
306.0	7001.3	MX	Pending	NK/A/2022/0.15772	08-Jun-2021						Treatment of ABCG6 Deficiency
306.0	7001.3	RU	Pending	202310.0002.5	08-Jun-2021			2023/0000.016		16-Feb-2023	Treatment of ABCG6 Deficiency
306.0	7001.3	CO	Published	NC2023/0000.016	08-Jun-2021			202347001.335		13-Jan-2023	Treatment of ABCG6 Deficiency
306.0	7001.3	IN	Published	202347001.335	08-Jun-2021			4009.0007A		27-Oct-2023	Treatment of ABCG6 Deficiency
306.0	7001.3	HK	Published	620230787.13.2	06-Sep-2023						Treatment of ABCG6 Deficiency
306.0	7000.3P4	US	Expired	63/285.085	01-Dec-2021						Treatment of ABCG6 Deficiency
306.0	7000.4P2	US	Expired	63/285.084	01-Dec-2021						Treatment of ABCG6 Deficiency
306.0	7001.4P1	US	Expired	63/297.153	04-Sep-2022						Treatment of ABCG6 Deficiency
306.0	7001.5P1	US	Expired	63/248.303	24-Sep-2022						Treatment of ABCG6 Deficiency
306.0	7001.5	US	Published	18/612.571	21-Mar-2024			US-2025-07.733.19-A1		06-Mar-2025	Treatment of ABCG6 Deficiency
306.0	7001.5	PC	Published	PC7/US22/769.69	23-Sep-2022			WO.202.3/049.864		30-Mar-2023	Treatment of ABCG6 Deficiency
306.0	7001.5	TW	Published	111.136.212	23-Sep-2022			2023.300.17		01-Aug-2023	Treatment of ABCG6 Deficiency
306.0	7001.5	AU	Pending	202395.3101	23-Sep-2022						Treatment of ABCG6 Deficiency
306.0	7001.5	BR	Published	BR11.202.4005324.5	23-Sep-2022			BR11.202.4005324.5		25-Jun-2024	Treatment of ABCG6 Deficiency
306.0	7001.5	CA	Published	3.231.858	23-Sep-2022			3231.858		30-Mar-2023	Treatment of ABCG6 Deficiency
306.0	7001.5	CN	Published	202280074276.7	23-Sep-2022			1182.155.07		18-Jun-2024	Treatment of ABCG6 Deficiency
306.0	7001.5	CO	Published	NC2024/0004.755	23-Sep-2022			2024/0004.755		10-May-2024	Treatment of ABCG6 Deficiency
306.0	7001.5	EP	Published	228738.96.5	23-Sep-2022			4404.960		31-Jul-2024	Treatment of ABCG6 Deficiency
306.0	7001.5	IN	Published	202447032.256	23-Sep-2022			202447032.256		26-Apr-2024	Treatment of ABCG6 Deficiency
306.0	7001.5	IL	Pending	3115.78	23-Sep-2022						Treatment of ABCG6 Deficiency
306.0	7001.5	JP	Published	2024-518.385	23-Sep-2022			2024-536.821		06-Oct-2024	Treatment of ABCG6 Deficiency
306.0	7001.5	KR	Published	10-2024-7012.631	23-Sep-2022			10-2024-00647.07		13-May-2024	Treatment of ABCG6 Deficiency

